- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Robert L. Coleman, MD, FACOG, FACS | Authors
Articles
Results of the VELIA Trial in Ovarian Cancer
September 28, 2019
Video
Robert L. Coleman, MD, FACOG, FACS, discusses the results of the phase III VELIA trial in patients with advanced ovarian cancer.
The Importance of Early BRCA Testing in Ovarian Cancer
June 10, 2016
Video
Robert L. Coleman, MD, discusses the importance of early BRCA testing for patients with ovarian cancer.
Patients With Ovarian Cancer Likely to Respond to Rucaparib Using Tumor Genetic Analysis
June 10, 2015
Video
Robert L. Coleman, MD, FACOG, FACS, professor, Ann Rife Cox Chair in Gynecology, Department of Gynecologic Oncology and Reproductive Medicine, vice chair, Clinical Research, The University of Texas MD Anderson Cancer Center, discusses the results of the ARIEL2 trial, a phase II study to identify patients with ovarian cancer likely to respond to rucaparib using tumor genetic analysis.
Impact of Bevacizumab in Ovarian Cancer
April 29, 2015
Video
Robert L. Coleman, MD, FACOG, FACS, professor, Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, discusses a study which examined the impact of bevacizumab in ovarian cancer.
The Results and Key Takeaways From GOG0213
March 28, 2015
Article
Robert L. Coleman, MD, FACOG, FACS, professor, The University of Texas MD Anderson Cancer Center, discusses the results and key takeaways from GOG0213.